Human Milk Oligosaccharides, Gut Bifidobacterium, Vitamin D, and Infant Immunity (HMO-BIFIDI)
Human Milk Oligosaccharides in Breast Milk and Its Relation to Gut Bifidobacterium, Vitamin D and Immune Modulation in Infants
The goal of this observational study is to learn how certain natural sugar components in breast milk may be linked with vitamin D level, healthy gut bacteria, and immune markers in healthy breastfed infants. The study will include exclusively breastfeeding mothers and their healthy infants aged 1 to 2 months.
The main questions it aims to answer are:
- Is this natural sugar in breast milk linked with the baby's vitamin D level?
- Is this natural sugar in breast milk linked with healthy gut bacteria?
- Is this baby's vitamin D level linked with healthy gut bacteria?
- Is this natural sugar linked with immune factors in breast milk? Participants will answer health questions from questionnaire, undergo a brief physical examination, allow breast milk and a small baby blood sample to be collected, and provide an baby stool sample.
Researchers will test these samples in the laboratory and analyze the results to answer the research questions.
調査の概要
状態
条件
詳細な説明
Subject recruitment was conducted during immunization activities at community health centers (Puskesmas) and integrated health posts (Posyandu). The subject collection technique used the quota sampling method, a non-probability subject selection technique carried out by determining the desired sample size (quota) from a population with predetermined criteria, and researchers collected sample units until the target quota was reached. Researchers provided an explanation of the research protocol and obtained informed consent from participants regarding their willingness to participate in the study. Participants who met the eligibility criteria (inclusion and exclusion criteria) were declared as research subjects. Next, a research questionnaire was completed, including recording the subject's identity (mother and baby), the mother's health and nutritional history, childbirth and breastfeeding history, observation of the baby's stool, history and risk factors for allergies, and a general physical examination.
Mature breast milk samples will be analyzed to determine maternal secretion status, HMO status, Bifidobacterium in breast milk, and the status of immune markers such as sCD14, TGF-beta, and IgA in breast milk. Stool samples will be analyzed to determine the infant's intestinal Bifidobacterium. Blood samples will also be analyzed to determine vitamin D levels. Statistical correlations between these parameters will be performed to determine the research objectives.
The collected data is grouped based on the purpose and type of data, then the appropriate statistical method is selected, namely:
- Univariate analysis (Used to describe basic data characteristics, in the form of frequency, mean value, standard deviation, and range)
Bivariate analysis
Comparison Test (To see differences between groups)
- Chi-Square Test → If the variable is categorical (e.g., the relationship between maternal secretory status (Secretory vs. Non-Secretory) and delivery method (Vaginal vs. Cesarean section). An alternative test, the Fisher's Exact test, is performed if the basic assumptions of the Chi-Square are not met.
- T-Test (Independent T-Test) → If you want to compare the means of two groups (e.g., the difference in vitamin D levels between male and female infants). An alternative test, the Mann-Whitney test, is used if the data is not normally distributed.
- ANOVA Test → If you want to compare the means of more than two groups (e.g., the difference in vitamin D levels based on the timing of early breastfeeding initiation: <1 hour, 1-6 hours, >6 hours). An alternative test, the Kruskal-Wallis test, is used if the data is not normally distributed.
Correlation Analysis (To see the relationship between two numeric variables)
- Pearson Correlation → If the data is normally distributed.
- Spearman Correlation → If the data is not normally distributed or is ordinal
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
South Sulawesi
-
Makassar、South Sulawesi、インドネシア、90245
- Hasanuddin University
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
Maternal Subject :
- Women aged at least 18 years who are physically healthy;
- Have a healthy baby aged 1-2 months with a full-term gestational age (37-42 weeks) and a normal birth weight (2500-4000 grams);
- Exclusively breastfeeding;
- Agree to participate in this study by signing an informed consent form.
Infant Subjects :
- All infants of mothers who meet the inclusion criteria
Exclusion Criteria:
Maternal Subject :
- Currently participating in another clinical trial;
- Having a condition such as a breast abscess or other breast pathology;
- Currently taking medications for conditions that may affect breast milk, such as antibiotics;
- Subjects who cannot comply with the study protocol
Infant Subjects:
- Currently participating in another clinical trial;
- Having a history of antimicrobial treatment (oral or parenteral antibiotics);
- Subjects are unable to comply with the research protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Analysis maternal Human Milk Oligosaccharides (HMO) and Breast Milk (BM) Bifidobacterium and their correlation to gut Bifidobacterium, serum vitamin D and immune regulatory status in infants
時間枠:At enrollment (single time point, cross-sectional assessment)
|
This outcome analyze the correlation between maternal human milk oligosaccharide (secretor status, 2FL' level), Breast Milk (BM) Bifidobacterium, gut Bifidobacterium, serum vitamin D and immune regulatory status in infants in infants aged 1 to 2 months.
|
At enrollment (single time point, cross-sectional assessment)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Association between maternal HMO and infant gut Bifidobacterium
時間枠:At enrollment (single time point, cross-sectional assessment)
|
Association between maternal human milk oligosaccharide (secretor status and 2FL' level) and Bifidobacterium abundance in infant stool.
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between maternal HMO and infant vitamin D level
時間枠:At enrollment (single time point, cross-sectional assessment)
|
Association between maternal human milk oligosaccharide (secretor status and 2FL' level) and vitamin D level in infant serum.
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between maternal HMO and breast milk immune markers
時間枠:At enrollment (single time point, cross-sectional assessment)
|
This outcome assesses the association between human milk oligosaccharide (HMO) (secretor status and 2FL' level) in breast milk and immune markers in breast milk, including soluble CD14 (sCD14), transforming growth factor beta (TGF-beta), and immunoglobulin A (IgA).
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between breast milk Bifidobacterium and infant gut microbiota
時間枠:At enrollment (single time point, cross-sectional assessment)
|
This outcome assesses the association between Bifidobacterium composition in breast milk and gut microbiota (Bifidobacterium) composition in infant stool samples.
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between breast milk Bifidobacterium and infant vitamin D level
時間枠:At enrollment (single time point, cross-sectional assessment)
|
This outcome assesses the association between Bifidobacterium composition in breast milk and vitamin D level in infant serum.
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between breast milk Bifidobacterium and breast milk immune marker
時間枠:At enrollment (single time point, cross-sectional assessment)
|
This outcome assesses the association between Bifidobacterium composition in breast milk and immune markers in breast milk, including soluble CD14 (sCD14), transforming growth factor beta (TGF-beta), and immunoglobulin A (IgA).
|
At enrollment (single time point, cross-sectional assessment)
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Bahrul Fikri, MD, Ph.D、Department of Pediatrics, Faculty of Medicine, Hasanuddin University
- スタディディレクター:Andi Raisyiah Akrimah Imran, MD, MHA、Department of Public Health and Family Medicine, Faculty of Medicine, Hasanuddin University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。